Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Operating Expenses (2016 - 2025)

United Therapeutics' Operating Expenses history spans 17 years, with the latest figure at $433.5 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 14.62% year-over-year to $433.5 million; the TTM value through Dec 2025 reached $1.7 billion, up 12.65%, while the annual FY2025 figure was $1.7 billion, 12.65% up from the prior year.
  • Operating Expenses for Q4 2025 was $433.5 million at United Therapeutics, up from $411.0 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $443.9 million in Q1 2021 and bottomed at $173.9 million in Q1 2022.
  • The 5-year median for Operating Expenses is $318.6 million (2022), against an average of $321.0 million.
  • The largest annual shift saw Operating Expenses skyrocketed 134.12% in 2021 before it tumbled 60.82% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $245.4 million in 2021, then increased by 28.73% to $315.9 million in 2022, then increased by 12.25% to $354.6 million in 2023, then grew by 6.66% to $378.2 million in 2024, then grew by 14.62% to $433.5 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Operating Expenses are $433.5 million (Q4 2025), $411.0 million (Q3 2025), and $434.1 million (Q2 2025).